Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
申请人:Cytovia, Inc.
公开号:US20030013743A1
公开(公告)日:2003-01-16
The present invention is directed to substituted N′-(arylcarbonyl)-benzhydrazides, N′-(arylcarbonyl)-benzylidene-hydrazides and analogs thereof, represented by the Formulae I and II:
1
wherein Ar
1
, Ar
2
, and R
1
-R
2
are defined herein. The present invention also relates to the discovery that compounds having Formulae I and II are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
Disclosed are compounds of formula I
1
wherein A, R1, R2, R3, R4 and R5 are described in the specification, pharmaceutical formulations comprising these compounds, the use of these compounds as medicaments, the use of these medicaments in the treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (NIDDM or Type 2 diabetes), as well as methods for treating diabetes comprising administration of these compounds.
natural naphthoquinone derivatives containing diaryl ether were designed and synthesized based on the binding model of lawsone and PS II D1. Bioassays exhibited that most compounds had more than 80% inhibition of Portulaca oleracea and Echinochloa crusgalli roots at a dose of 100 μg/mL and compounds B4, B5, and C3 exhibited superior herbicidalactivities against dicotyledonous and monocotyledon weeds to
光合作用系统II(PS II)是生物除草剂开发的重要目标。本研究基于指甲花松和PS II D1的结合模型,设计合成了一系列含有二芳基醚的天然萘醌衍生物。生物测定表明,大多数化合物在100 μg/mL的剂量下对马齿苋和稗草根的抑制率超过80%,并且化合物B4 、 B5和C3对双子叶和单子叶杂草表现出优于市售莠去津的除草活性。特别地,化合物B5在150g ai/ha的剂量下表现出优异的除草活性。此外,与莠去津相比,化合物B5对农作物的损害较小。分子对接研究表明,化合物B5通过多种相互作用模型(例如 π-π 堆积和氢键)与豌豆PS II D1 有效相互作用。分子动力学模拟研究和叶绿素荧光测量表明,化合物B5作用于 PS II。这是针对PS II的天然萘醌衍生物的首次报道,化合物B5可能是开发针对PS II的新型除草剂的候选分子。
Design, synthesis and biological evaluation of pyridine-phenylpiperazines: A novel series of potent and selective α1a-adrenergic receptor antagonist
Beginning from the screening hit and literature alpha(1)-adrenergic compounds, a hybridized basic skeleton A was proposed as the pharmacophore for potent and selective alpha(1a)-AR antagonists. Introduction of a hydroxy group to increase the flexibility afforded B which served as the screening model and resulted in the identification of the second-generation lead 1. Using the Topliss approach, a number of potent and selective alpha(1a)-AR antagonists were discovered. In all cases, binding affinity and selectivity at the alpha(1a)-AR of S-hydroxy enantiomers were higher than the R-hydroxy enantiomers. As compared to the des-hydroxy analogues, the S-hydroxy enantiomers displayed comparable potency and better selectivity at alpha(1a)-AR. The S-hydroxy enantiomer 17 (K-i = 0.79 nM; alpha(1b)/alpha(1a) = 800; alpha(1d)/alpha(1a) = 104) was slightly less potent but much more selective at alpha(1a)-AR than tamsulosin (K-i = 0.13 nM, alpha(1b)/alpha(1a) = 15, alpha(1d)/alpha(1a) = 1.4). Compound 17 displayed higher selectivity in inhibiting rat prostate contraction over rat aorta contraction and also exhibited a higher degree of uroselectivity than tamsulosin in the anesthetized dog model. (C) 2000 Elsevier Science Ltd. All rights reserved.
NOVEL SUBSTITUTED PYRIDINO ARYLPIPERAZINES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA